There are interesting, exciting new developments in cancer treatments all the time. The following is particularly relevant for late stage HER2 positive bc.
Targeted Therapy Leads 2012 Cancer Advances
Targeted therapies for metastatic HER2-positive breast cancer are among this year’s top advances in oncology, according to a report from the American Society of Clinical Oncology (ASCO).
The recently approved pertuzumab (Perjeta) was lauded for slowing disease progression in advanced breast cancer when added to standard therapy, according to Bruce Roth, MD, of Washington University in St. Louis, co-executive editor of the report, and colleagues.
Following at a close second was the investigational agent T-DM1, a “smart bomb” of chemotherapy guided directly to breast cancer cells by a monoclonal antibody.
“Major advances over the past year were achieved in the areas of overcoming treatment resistance, personalized medicine, and screening,” the researchers wrote.
In addition to pertuzumab, oncology had an explosion of new therapeutics in 2012, including a total of seven new compounds and five expanded approvals for existing drugs.
The pertuzumab approval came in June following two phase III trials, which found that when the drug was combined with trastuzumab (Herceptin) and docetaxel (Taxotere), it delayed disease progression significantly more than the two standard drugs alone. T-DM1 is currently under consideration for approval by the FDA.
Primary source: ASCO
Roth BJ, et al “Clinical cancer advances 2012” ASCO 2012.